Long-term, phase 2, multicenter, double-blind, parallel group extension study in patients with rheumatoid arthritis who have completed a previous phase 2, randomized, controlled trial with ABBV-105 administered alone or in combination with upadacitinib (ABBV -599)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ABBVIE SPAIN SLU
- Phase: II
- Execution start: 10/05/2019
- End of execution: 30/10/2023
- IP: RAFAEL CALIZ CALIZ